Ben Jones, vice president, Government Relations & Public Policy, McKesson Specialty Health, discusses the importance of capturing real-world evidence in electronic health records (EHRs) and challenges oncologists face when trying to obtain these data from EHRs.
Ben Jones, vice president, Government Relations & Public Policy, McKesson Specialty Health, discusses the importance of capturing real-world evidence in electronic health records (EHRs) and challenges oncologists face when trying to obtain these data from EHRs.
Transcript
How important is capturing real-world evidence in EHRs for improving the care of patients?
From a policy perspective, as all of these proposals come around, they have 1 central theme, and that is trying to drive towards value. Every policy maker wants to do 2 things: they want to increase coverage and reduce costs. That’s very difficult to do unless you can figure out how to drive efficiency and drive toward value. The only way to drive toward value is to make sure that we’ve got a good handle on patient data, and we see how we’re measuring outcomes. We see what’s working, we see what’s not working. We use all of these tools that we believe are driving value and we capture the data to make sure that’s actually the case. As that drive toward value continues, patient data is going to be very important.
Is this real-world evidence easily accessible currently, or are there challenges oncologists experience when trying to obtain these data from EHRs?
It’s still very difficult. Technology had progressed over the last decade by leaps and bounds. Unfortunately, the more desire there is to catch data, sometimes, often times, that means an increased burden from the provider’s perspective. So, there still is that barrier. I think everybody recognizes the value in data, the need and the necessity to gather data and have data that you can trust, that is fully in-depth enough to be of value down the road. The problem then becomes do we have the right systems in place to make sure that burden is not so much that we’re reducing the value of data down the road?
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More